Skip to main content

Main menu

  • Home
  • About
    • About CBM
    • Editorial Board
    • Announcement
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Other Publications
    • cbm

User menu

  • My alerts

Search

  • Advanced search
Cancer Biology & Medicine
  • Other Publications
    • cbm
  • My alerts
Cancer Biology & Medicine

Advanced Search

 

  • Home
  • About
    • About CBM
    • Editorial Board
    • Announcement
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Follow cbm on Twitter
  • Visit cbm on Facebook
Research ArticleOriginal Article

Loss of NEIL3 activates radiotherapy resistance in the progression of prostate cancer

Qiong Wang, Zean Li, Jin Yang, Shirong Peng, Qianghua Zhou, Kai Yao, Wenli Cai, Zhongqiu Xie, Fujun Qin, Hui Li, Xu Chen, Kaiwen Li and Hai Huang
Cancer Biology & Medicine August 2022, 19 (8) 1193-1210; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0550
Qiong Wang
1Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China
2Department of Pathology, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA
3Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zean Li
1Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China
3Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jin Yang
3Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China
4Department of Radiation Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shirong Peng
1Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China
3Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qianghua Zhou
1Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China
3Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kai Yao
5Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wenli Cai
6Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhongqiu Xie
2Department of Pathology, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fujun Qin
2Department of Pathology, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hui Li
2Department of Pathology, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xu Chen
1Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China
3Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kaiwen Li
1Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China
3Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kaiwen Li
  • For correspondence: huangh9{at}mail.sysu.edu.cn likw6{at}mail.sysu.edu.cn
Hai Huang
1Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China
3Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China
7Department of Urology, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People’s Hospital, Qingyuan 511518, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Hai Huang
  • For correspondence: huangh9{at}mail.sysu.edu.cn likw6{at}mail.sysu.edu.cn
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Supplementary Materials
  • Figure 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1

    RNA microarray and database-integrated screening identified that NEIL3 correlated with the progression of PCa. (A) Three target genes were selected from the microarray, CRPC database, NEPC database and TCGA BCR survival analysis. (B, C) BCR survival analysis of NEIL3 in TCGA datasets and Sun Yat-sen University Cancer Center patients. (D, E) The expression of NEIL3 in our CRPC microarray and GSE33316. (F) RT-PCR detection of NEIL3 mRNA levels in PC3-derived NEPC cells; *P < 0.05 and **P < 0.01, versus the PC3-ctrl group. (G, H) Representative active immunohistochemical staining and quantification showing the expression level of NEIL3 in TMA (G) and Sun Yat-sen University Cancer Center (H) PCa tissues.

  • Figure 2
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2

    NEIL3 has no effect on the proliferation and migration of PCa cells in vitro. (A) Colony formation assay test cell viability in DU145 and PC3 cell lines when NEIL3 was overexpressed or downregulated. (B) Statistical analysis of the number of colonies between different groups. (C–F) The MTS assay test of cell viability in DU145 (C, D) and PC3 (E, F) cells when NEIL3 was overexpressed or downregulated. (G and I) Representative images of migration assays using DU145 and PC3 cells after downregulation or upregulation of NEIL3. (H and J) Histogram analysis of migrated cell counts showing cell migration after downregulation or upregulation of NEIL3.

  • Figure 3
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3

    NEIL3 facilitates radiotherapy sensitivity of PCa cells in vitro and in vivo. (A) BCR survival analysis of NEIL3 in TCGA radiotherapy patients. (B) Colony formation assay test cell viability in DU145 and PC3 cell lines after radiotherapy when NEIL3 was overexpressed or downregulated. (C) Statistical analysis of the number of colonies between different groups; *P < 0.05 and **P < 0.01 between groups. (D–G) The MTS assay test of cell viability in DU145 (D, E) and PC3 (F, G) cells after radiotherapy when NEIL3 was overexpressed or downregulated; *P < 0.05, **P < 0.01 and ****P < 0.0001, versus the corresponding vector or NC group. (H) Gross observation of the nude BALB/c xenografts and radiotherapy mouse model. (I) Tumor reduction curves of the NEIL3 overexpression and control groups are summarized in the line chart after radiotherapy. The average tumor volume is expressed as the mean ± SD. (J) Representative HE and immunohistochemical staining of xenograft tumors before and after radiotherapy; 400×, scale bars = 100 μm.

  • Figure 4
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4

    NEIL3 promotes radiotherapy sensitivity by not affecting apoptosis. (A–D) Representative flow cytometry cell apoptosis images (A, B) and histogram analysis of apoptotic cell counts (C, D) of DU145 before and 48 h after radiotherapy in the NEIL3 overexpression or NEIL3 knockdown groups. (E–H) Representative flow cytometry cell apoptosis images (E, F) and histogram analysis of apoptotic cell counts (G, H) of DU145 before and 48 h after radiotherapy in the NEIL3 overexpression or NEIL3 knockdown groups.

  • Figure 5
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5

    NEIL3 promotes radiotherapy sensitivity by regulating the cell cycle. (A and B) Representative flow cytometry cell cycle images of DU145 (A) and PC3 (B) cells before and 6 h, 12 h, and 24 h after radiotherapy. (C–F) Relative G2-phase change curves of NEIL3 overexpression (C, E) or knockdown (D, F) in DU145 and PC3 cell lines; *P < 0.05, **P < 0.01, and ****P < 0.0001, versus the corresponding time point vector or NC group.

  • Figure 6
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6

    NEIL3 regulates the cell cycle through the ATR/CHK1 pathway. (A and B) Representative image of the Western blot analysis of NEIL3, TOPBP1, ATR, phosphorylated ATR, phosphorylated CHK1 and γ-H2AX protein levels after NEIL3 knockdown or overexpression in DU145 (A) and PC3 (B) cells. (C) Pathway illustration of NEIL3 influencing the ATR/CHK1 pathway.

Tables

  • Figures
  • Supplementary Materials
    • View popup
    Table 1

    Correlation of NEIL3 expression with clinico-pathologic characteristics of PCa patients in TCGA database (78 radiotherapy patients)

    Clinical featuresTotal patients, nLow, n (%)High, n (%)P
    Age, years0.194
     ≤ 655824 (41.4%)34 (58.6%)
     > 65205 (25%)15 (75%)
    Gleason score0.017*
     ≤ 71811 (61.1%)7 (38.9%)
     > 76018 (30%)42 (70%)
    Serum PSA levels, ng/mL0.826
     ≤ 46625 (37.9%)41 (62.1%)
     > 462 (33.3%)4 (66.7%)
    T stage0.051
     T1-T286 (75%)2 (25%)
     T3-T47023 (32.9%)47 (67.1%)
    Lymph node metastasis0.492
     N04415 (34.1%)29 (65.9%)
     N12611 (42.3%)15 (57.7%)
    Distant metastasis1.000
     M07026 (37.1%)44 (62.9%)
     M110 (0%)1 (100%)

    Cut off value of NEIL3 score: medium; PSA, prostate‑specific antigen; T, tumor; N, node; M, metastasis. *P < 0.05.

      • View popup
      Table 2

      Correlation of NEIL3 expression with clinico-pathologic characteristics of PCA patients in Sun Yat-sen University Cancer Center (99 patients)

      Clinical featuresTotal patients, nLow, n (%)High, n (%)P
      Age, years1.000
       ≤ 654428 (63.6%)16 (36.4%)
       > 655535 (63.6%)20 (36.4%)
      Gleason score0.036*
       ≤ 7 (3 + 4)4433 (75%)11 (25%)
       ≥ 7 (4 + 3)5530 (54.5%)25 (45.5%)
      Serum PSA levels, ng/mL0.751
       ≤ 43523 (65.7%)12 (34.3%)
       > 46440 (62.5%)24 (37.5%)
      T stage1.000
       T1–T22015 (75%)5 (25%)
       T3–T43628 (77.8%)8 (22.2%)
      Lymph node metastasis0.654
       N03829 (76.3%)9 (23.7%)
       N12820 (71.4%)8 (28.6%)
      Distant metastasis0.586
       M02115 (71.4%)6 (28.6%)
       M12214 (63.6%)8(36.4%)

      Cut off value of immuno-reactivity score: 6 (> 6, High; ≤ 6, Low.); T, tumor; N, node; M, metastasis. *P < 0.05.

      Supplementary Materials

      • Figures
      • Tables
      • [cbm-19-1193-s001.pdf]
      PreviousNext
      Back to top

      In this issue

      Cancer Biology & Medicine: 19 (8)
      Cancer Biology & Medicine
      Vol. 19, Issue 8
      15 Aug 2022
      • Table of Contents
      • Index by author
      Print
      Download PDF
      Email Article

      Thank you for your interest in spreading the word on Cancer Biology & Medicine.

      NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

      Enter multiple addresses on separate lines or separate them with commas.
      Loss of NEIL3 activates radiotherapy resistance in the progression of prostate cancer
      (Your Name) has sent you a message from Cancer Biology & Medicine
      (Your Name) thought you would like to see the Cancer Biology & Medicine web site.
      Citation Tools
      Loss of NEIL3 activates radiotherapy resistance in the progression of prostate cancer
      Qiong Wang, Zean Li, Jin Yang, Shirong Peng, Qianghua Zhou, Kai Yao, Wenli Cai, Zhongqiu Xie, Fujun Qin, Hui Li, Xu Chen, Kaiwen Li, Hai Huang
      Cancer Biology & Medicine Aug 2022, 19 (8) 1193-1210; DOI: 10.20892/j.issn.2095-3941.2020.0550

      Citation Manager Formats

      • BibTeX
      • Bookends
      • EasyBib
      • EndNote (tagged)
      • EndNote 8 (xml)
      • Medlars
      • Mendeley
      • Papers
      • RefWorks Tagged
      • Ref Manager
      • RIS
      • Zotero
      Share
      Loss of NEIL3 activates radiotherapy resistance in the progression of prostate cancer
      Qiong Wang, Zean Li, Jin Yang, Shirong Peng, Qianghua Zhou, Kai Yao, Wenli Cai, Zhongqiu Xie, Fujun Qin, Hui Li, Xu Chen, Kaiwen Li, Hai Huang
      Cancer Biology & Medicine Aug 2022, 19 (8) 1193-1210; DOI: 10.20892/j.issn.2095-3941.2020.0550
      Twitter logo Facebook logo Mendeley logo
      • Tweet Widget
      • Facebook Like
      • Google Plus One

      Jump to section

      • Article
        • Abstract
        • Introduction
        • Materials and methods
        • Results
        • Discussion
        • Conclusions
        • Supporting Information
        • Grant support
        • Conflicts of interest statement
        • Author contributions
        • Footnotes
        • References
      • Figures & Data
      • Info & Metrics
      • References
      • PDF

      Related Articles

      • No related articles found.
      • Google Scholar

      Cited By...

      • No citing articles found.
      • Google Scholar

      More in this TOC Section

      • SPRED2 suppresses the stemness of hepatocellular carcinoma through the p53/miR-506-3p/KLF4 pathway
      • Migration and invasion inhibitory protein inhibits M2 macrophage polarization to suppress colorectal cancer progression through the STING–NFκB2–IL10 axis
      • Temporal radiomics for non-invasive preoperative prediction of pathologic complete response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer
      Show more Original Article

      Similar Articles

      Keywords

      • CRPC
      • NEIL3
      • NEPC
      • Prostate cancer
      • radiotherapy resistance

      Navigate

      • Home
      • Current Issue

      More Information

      • About CBM
      • About CACA
      • About TMUCIH
      • Editorial Board
      • Subscription

      For Authors

      • Instructions for authors
      • Journal Policies
      • Submit a Manuscript

      Journal Services

      • Email Alerts
      • Facebook
      • RSS Feeds
      • Twitter

       

      © 2026 Cancer Biology & Medicine

      Powered by HighWire